Relation of clinical response and minimal residual disease and their prognostic impact on outcome in acute myeloid leukemia

Journal of Clinical Oncology

Volumn 33, Issue 11, 2015, Pages 1258-1264

  Chen, Xueyan ^a   Xie, Hu ^b   Wood, Brent L ^a   Walter, Roland B ^b   Pagel, John M ^b   Becker, Pamela S ^b   Sandhu, Vicky K ^b   Abkowitz, Janis L ^a   Appelbaum, Frederick R ^b   Estey, Elihu H ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; MITOXANTRONE; ANTINEOPLASTIC AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; BLOOD CELL COUNT; BONE MARROW BIOPSY; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RECURRENCE; CONVALESCENCE; DRUG MEGADOSE; FEMALE; FLOW CYTOMETRY; FLT3 GENE; GENE; GENE DUPLICATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INDUCTION CHEMOTHERAPY; KARYOTYPE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; MONOSOMY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; ADOLESCENT; ADVERSE EFFECTS; BLOOD; BONE MARROW EXAMINATION; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; GENETICS; KAPLAN MEIER METHOD; LEUKEMIA, MYELOID, ACUTE; LEUKOCYTE COUNT; MIDDLE AGED; MORTALITY; NEUTROPHIL; PATHOLOGY; PREDICTIVE VALUE; PROPORTIONAL HAZARDS MODEL; RECURRENT DISEASE; REMISSION; RISK FACTOR; THROMBOCYTE; THROMBOCYTE COUNT; TIME; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOOD PLATELETS; BONE MARROW EXAMINATION; DISEASE-FREE SURVIVAL; FEMALE; FLOW CYTOMETRY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INDUCTION CHEMOTHERAPY; KAPLAN-MEIER ESTIMATE; LEUKEMIA, MYELOID, ACUTE; LEUKOCYTE COUNT; MALE; MIDDLE AGED; NEOPLASM, RESIDUAL; NEUTROPHILS; PLATELET COUNT; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RECURRENCE; REMISSION INDUCTION; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84927127471     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.58.3518     Document Type: Article

References (38)

1. Burnett AK, Goldstone AH, Stevens RM, et al: Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: Results of MRC AML 10 trial-UK Medical Research Council Adult and Children's Leukaemia Working Parties. Lancet 351:700-708, 1998
2. Ferrara F, Schiffer CA: Acute myeloid leukaemia in adults. Lancet 381:484-495, 2013
3. Lowenberg B: Strategies in the treatment of acute myeloid leukemia. Haematologica 89:1029-1032, 2004
4. Walter RB, Othus M, Ho PA, et al: Prediction of therapeutic resistance in adult acute myeloid leukemia: Analysis of 4,550 newly diagnosed patients from MRC/NCRI, HOVON/SAKK, SWOG, and MD Anderson Cancer Center. Blood 122, 2013 (abstr 64)
5. Im AP, Sehgal AR, Carroll MP, et al: DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: Associations with prognosis and potential treatment strategies. Leukemia 28:1774-1783, 2014
6. Venditti A, Buccisano F, Del Poeta G, et al: Level of minimal residual disease after consolidation therapy predicts outcome in acute myeloid leukemia. Blood 96:3948-3952, 2000
7. Kern W, Voskova D, Schoch C, et al: Determination of relapse risk based on assessment of minimal residual disease during complete remission by multiparameter flow cytometry in unselected patients with acute myeloid leukemia. Blood 104: 3078-3085, 2004
8. Buccisano F, Maurillo L, Gattei V, et al: The kinetics of reduction of minimal residual disease impacts on duration of response and survival of patients with acute myeloid leukemia. Leukemia 20:1783-1789, 2006
9. San Miguel JF, Vidriales MB, López-Berges C, et al: Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification. Blood 98:1746-1751, 2001
10. Terwijn M, van Putten WL, Kelder A, et al: High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: Data from the HOVON/SAKK AML 42A study. J Clin Oncol 31:3889-3897, 2013
11. Yin JA, O'Brien MA, Hills RK, et al: Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: Results of the United Kingdom MRC AML-15 trial. Blood 120:2826-2835, 2012
12. Krönke J, Schlenk RF, Jensen KO, et al: Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: A study from the German-Austrian Acute Myeloid Leukemia Study Group. J Clin Oncol 29:2709-2716, 2011
13. Jourdan E, Boissel N, Chevret S, et al: Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia. Blood 121:2213-2223, 2013
14. Freeman SD, Virgo P, Couzens S, et al: Prognostic relevance of treatment response measured by flow cytometric residual disease detection in older patients with acute myeloid leukemia. J Clin Oncol 31:4123-4131, 2013
15. Walter RB, Kantarjian HM, Huang X, et al: Effect of complete remission and responses less than complete remission on survival in acute myeloid leukemia: A combined Eastern Cooperative Oncology Group, Southwest Oncology Group, and M. D. Anderson Cancer Center study. J Clin Oncol 28:1766-1771, 2010
16. Medeiros BC, Othus M, Fang M, et al: Prognostic impact of monosomal karyotype in young adult and elderly acute myeloid leukemia: The Southwest Oncology Group (SWOG) experience. Blood 116:2224-2228, 2010
17. Slovak ML, Kopecky KJ, Wolman SR, et al: Cytogenetic correlation with disease status and treatment outcome in advanced stage leukemia post bone marrow transplantation: A Southwest Oncology Group study (SWOG-8612). Leuk Res 19:381-388, 1995
18. Mrózek K, Heerema NA, Bloomfield CD: Cytogenetics in acute leukemia. Blood Rev 18:115-136, 2004
19. Grimwade D, Hills RK, Moorman AV, et al: Refinement of cytogenetic classification in acute myeloid leukemia: Determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 116:354-365, 2010
20. Cheson BD, Bennett JM, Kopecky KJ, et al: Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 21:4642-4649, 2003
21. Wood B: 9-color and 10-color flow cytometry in the clinical laboratory. Arch Pathol Lab Med 130: 680-690, 2006
22. Kussick SJ, Fromm JR, Rossini A, et al: Fourcolor flow cytometry shows strong concordance with bone marrow morphology and cytogenetics in the evaluation for myelodysplasia. Am J Clin Pathol 124:170-181, 2005
23. Wood BL: Myeloid malignancies: Myelodysplastic syndromes, myeloproliferative disorders, and acute myeloid leukemia. Clin Lab Med 27:551-575, 2007
24. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
25. Gooley TA, Leisenring W, Crowley J, et al: Estimation of failure probabilities in the presence of competing risks: New representations of old estimators. Stat Med 18:695-706, 1999
26. Breems DA, Van Putten WL, De Greef GE, et al: Monosomal karyotype in acute myeloid leukemia: A better indicator of poor prognosis than a complex karyotype. J Clin Oncol 26:4791-4797, 2008
27. Swerdlow SH, Campo E, Harris NL, et al: (eds): WHO Classification of Tumours of Haematopoietic and Lymphoid Tissue (ed 4). Geneva, Switzerland, WHO Press, 2008
28. Elliott MA, Litzow MR, Letendre LL, et al: Early peripheral blood blast clearance during induction chemotherapy for acute myeloid leukemia predicts superior relapse-free survival. Blood 110: 4172-4174, 2007
29. Vainstein V, Buckley SA, Shukron O, et al: Rapid rate of peripheral blood blast clearance accurately predicts complete remission in acute myeloid leukemia. Leukemia 28:713-716, 2014
30. Yan CH, Liu DH, Liu KY, et al: Risk stratification-directed donor lymphocyte infusion could reduce relapse of standard-risk acute leukemia patients after allogeneic hematopoietic stem cell transplantation. Blood 119:3256-3262, 2012
31. Rubnitz JE, Inaba H, Dahl G, et al: Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: Results of the AML02 multicentre trial. Lancet Oncol 11:543-552, 2010
32. Grimwade D, Jovanovic JV, Hills RK, et al: Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy. J Clin Oncol 27:3650-3658, 2009
33. Zhu HH, Zhang XH, Qin YZ, et al: MRDdirected risk stratification treatment may improve outcomes of t(8;21) AML in the first complete remission: Results from the AML05 multicenter trial. Blood 121:4056-4062, 2013
34. Platzbecker U, Wermke M, Radke J, et al: Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: Results of the RELAZA trial. Leukemia 26:381-389, 2012
35. Dvoř áková M, Karafiát V, Pajer P, et al: DNA released by leukemic cells contributes to the disruption of the bone marrow microenvironment. Oncogene 32:5201-5209, 2013
36. Walter RB, Buckley SA, Pagel JM, et al: Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission. Blood 122:1813-1821, 2013
37. Walter RB, Gooley TA, Wood BL, et al: Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia. J Clin Oncol 29:1190-1197, 2011
38. Mantel N, Byar DP: Evaluation of responsetime data involving transient states: An illustration using heart-transplant data. J Am Stat Assoc 69:81-86, 1974